Skye Bioscience Inc (SKYE)

$1.30 -0.07 (-5.11%)
Market Cap 48.73M
Revenue (ttm) 0.00
Net Income (ttm) -26.57M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 221,088
Avg Vol 976,042
Day's Range N/A - N/A
Shares Out 32.06M
Stochastic %K 4%
Beta 2.28
Analysts Strong Sell
Price Target $8.71

Company Profile

Skye Bioscience, Inc., a clinical stage biopharmaceutical company, focuses on developing molecules that modulate G protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in Jan...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 410 0266
Address:
11250 El Camino Real, Suite 100, San Diego, United States
HedgeAlerts
HedgeAlerts Nov. 14 at 6:09 PM
Hedge Alert Live - Protect Your Portfolio Contract: $SKYE $2.50 Put · NOV 21, 2025 Exp Entry Price: $1.15 - $1.20 Exit Price Target: $1.95 Profit Margin: +70% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 14 at 5:08 PM
💎 LiquidTheta® Live Actionable Trade Asset: $SKYE Contracts: $SKYE June 18, 2026 $2 Calls Scale in: $0.52- $0.64 Scale out: $2.03-$3.48 Profit Potential : 68% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
YazzJr
YazzJr Nov. 14 at 3:09 PM
$SKYE Not much holding this stock up. We have til what,Feb until we get the results for the 300mg dosage? That is a ways away. If this goes much lower we are going to have to start worrying about NASDAQ compliance issues. Hopefully they can find a partner or a buyer some time soon. Really need some kind of good news here soon.
1 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 7:29 AM
Hedge Alert Live - Protect Your Portfolio Contract: $SKYE $2.50 Put · NOV 21, 2025 Exp Entry Price: $1.15 - $1.20 Exit Price Target: $1.77 Profit Margin: +54% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 13 at 10:15 AM
💎 LiquidTheta® Live Actionable Trade Asset: $SKYE Contracts: $SKYE June 18, 2026 $2 Calls Scale in: $0.50- $0.61 Scale out: $1.93-$3.30 Profit Potential : 323% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
iMoveTheMarket
iMoveTheMarket Nov. 13 at 6:06 AM
$SKYE $VKTX I take this back. It’s aweful
0 · Reply
iMoveTheMarket
iMoveTheMarket Nov. 13 at 6:05 AM
$SKYE this is like a dog shit shit a dog shit
1 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 12 at 12:36 PM
💎 LiquidTheta® Live Actionable Trade Asset: $SKYE Contracts: $SKYE June 18, 2026 $2 Calls Scale in: $0.38- $0.47 Scale out: $1.49-$2.55 Profit Potential : 444% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
MissionaryTrader
MissionaryTrader Nov. 12 at 1:38 AM
$SKYE Percentage of float shorted has dropped to 10.18%, this is down from around 19%
2 · Reply
iMoveTheMarket
iMoveTheMarket Nov. 11 at 11:05 PM
$VKTX $SKYE is the underrated stock here. 150mil market cap and its drug doesn’t take weight off but what it does do is it greatly reduces the amount of weight added back on over time
1 · Reply
Latest News on SKYE
Skye Bioscience, Inc. (SKYE) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 10:41 PM EST - 3 days ago

Skye Bioscience, Inc. (SKYE) Q3 2025 Earnings Call Transcript

Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update

Nov 10, 2025, 4:01 PM EST - 4 days ago

Skye Bioscience Reports Third Quarter 2025 Financial Results and Business Update

Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain

Nov 5, 2025, 7:05 AM EST - 9 days ago

Skye Bioscience Late-Breaking Oral Abstract at ObesityWeek 2025 to Highlight Improvement in Rebound Weight Gain

Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025

Nov 5, 2025, 7:00 AM EST - 9 days ago

Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025

Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

Oct 28, 2025, 8:00 AM EDT - 17 days ago

Step Pharma announces the appointment of Dr Karen Smith as Chief Medical Officer

CNTX

Skye Bioscience, Inc. - Special Call

Oct 6, 2025, 2:25 PM EDT - 5 weeks ago

Skye Bioscience, Inc. - Special Call

Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge

Oct 6, 2025, 1:09 PM EDT - 5 weeks ago

Nasdaq Jumps Over 150 Points; Skye Bioscience Shares Plunge

Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss

Oct 6, 2025, 10:39 AM EDT - 5 weeks ago

Skye Bioscience's Investigational Drug Disappoints As Monotherapy For Weight Loss

Skye Bioscience's obesity drug fails to meet main goal of mid-stage study

Oct 6, 2025, 7:09 AM EDT - 5 weeks ago

Skye Bioscience's obesity drug fails to meet main goal of mid-stage study

Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial

Oct 6, 2025, 7:00 AM EDT - 5 weeks ago

Skye Bioscience Reports Topline CBeyond™ Phase 2a Data from Nimacimab Monotherapy and Combination Clinical Trial

Skye Bioscience: Promising Nimacimab Data Supports Buy Rating

Oct 1, 2025, 10:45 AM EDT - 6 weeks ago

Skye Bioscience: Promising Nimacimab Data Supports Buy Rating

Could This New Drug Be The Safer Way To Fight Obesity?

Sep 19, 2025, 2:19 PM EDT - 2 months ago

Could This New Drug Be The Safer Way To Fight Obesity?

Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting

Sep 19, 2025, 7:00 AM EDT - 2 months ago

Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting

Skye Bioscience, Inc. (SKYE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 10, 2025, 9:45 AM EDT - 2 months ago

Skye Bioscience, Inc. (SKYE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data

Sep 5, 2025, 1:35 PM EDT - 2 months ago

Skye Bioscience Advances Position In Competitive Obesity Market With Promising Data

Skye Bioscience, Inc. (SKYE) Virtual KOL Event Transcript

Sep 5, 2025, 1:30 AM EDT - 2 months ago

Skye Bioscience, Inc. (SKYE) Virtual KOL Event Transcript

Skye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

Sep 4, 2025, 7:00 AM EDT - 2 months ago

Skye's CB1 Inhibitor, Nimacimab, Demonstrates Superior Weight Loss and Differentiated Mechanisms from Monlunabant, and Continues to Show Enhanced Combination with Tirzepatide with Durable Post-Treatment Weight Maintenance in DIO Model

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

Sep 2, 2025, 7:00 AM EDT - 2 months ago

Skye Completes 26-week Treatment Phase in Phase 2a CBeyond™ Study

Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout

Aug 27, 2025, 7:00 AM EDT - 2 months ago

Skye Bioscience to Host Virtual KOL Event and Provide Perspectives on Upcoming CBeyond™ Phase 2a Topline Clinical Data Readout

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

Aug 21, 2025, 7:00 AM EDT - 3 months ago

Skye Bioscience to Participate in Upcoming Investment and Medical Conferences

Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 8:36 PM EDT - 3 months ago

Skye Bioscience, Inc. (SKYE) Q2 2025 Earnings Call Transcript

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

Aug 7, 2025, 4:01 PM EDT - 3 months ago

Skye Bioscience Reports Second Quarter 2025 Financial Results and Business Update

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

Jul 30, 2025, 7:00 AM EDT - 3 months ago

Skye Bioscience to Announce Second Quarter 2025 Financial Results and Business Update on August 7, 2025

Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing

Jul 7, 2025, 11:59 PM EDT - 4 months ago

Skye Bioscience Partners With Arecor: Potentially Enhanced Nimacimab Dosing

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions

Jun 23, 2025, 7:00 AM EDT - 5 months ago

Skye Bioscience Shares Nimacimab “Anatomy of Progress” Video Series and Highlights Preclinical CB1 Antibody Data Presented at the American Diabetes Association's 85th Scientific Sessions

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions

Jun 17, 2025, 7:00 AM EDT - 5 months ago

Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association's 85th Scientific Sessions

Skye Bioscience to Participate in Upcoming Investment Conferences

May 22, 2025, 7:00 AM EDT - 6 months ago

Skye Bioscience to Participate in Upcoming Investment Conferences

Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

May 19, 2025, 5:00 AM EDT - 6 months ago

Skye Bioscience Establishes Partnership with Arecor Therapeutics to Develop Enhanced Formulation of Obesity Candidate Nimacimab

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

May 13, 2025, 4:05 PM EDT - 6 months ago

Skye Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity

May 13, 2025, 7:00 AM EDT - 6 months ago

Skye Bioscience Clinical Model Demonstrating Necessity of Peripheral CB1 Inhibition for Weight Loss Presented at European Congress on Obesity

Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call Transcript

May 9, 2025, 7:20 PM EDT - 6 months ago

Skye Bioscience, Inc. (SKYE) Q1 2025 Earnings Call Transcript

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity

May 8, 2025, 4:01 PM EDT - 6 months ago

Skye Bioscience Reports First Quarter 2025 Results and Highlights Nimacimab Differentiation in Obesity

Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025

May 7, 2025, 7:00 AM EDT - 6 months ago

Skye Bioscience to Announce 2025 First Quarter Financial Results on May 8th, 2025

Skye Bioscience to Participate in May Investment and Medical Conferences

Apr 29, 2025, 7:00 AM EDT - 7 months ago

Skye Bioscience to Participate in May Investment and Medical Conferences

A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value

Apr 16, 2025, 7:50 AM EDT - 7 months ago

A Weight Loss Drug Candidate Essentially For Free As Skye Bioscience Is Trading At Cash Value

Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models

Apr 15, 2025, 3:42 PM EDT - 7 months ago

Skye Bioscience's Obesity Candidate Shows 30% Weight Loss When Combined With Eli Lilly's Blockbuster Drug In Animal Models

LLY

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model

Apr 15, 2025, 7:00 AM EDT - 7 months ago

Skye Bioscience Demonstrates Over 30% Weight Loss with Nimacimab and Tirzepatide Combination in Preclinical Model

Skye Bioscience to Conduct Meetings at Piper Sandler Conference

Apr 14, 2025, 7:00 AM EDT - 7 months ago

Skye Bioscience to Conduct Meetings at Piper Sandler Conference

Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call Transcript

Mar 20, 2025, 9:58 PM EDT - 8 months ago

Skye Bioscience, Inc. (SKYE) Q4 2024 Earnings Call Transcript

Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025

Mar 14, 2025, 7:00 AM EDT - 8 months ago

Skye Bioscience to Announce 2024 Financial Results on March 20th, 2025

Skye Bioscience to Present at TD Cowen Health Care Conference

Feb 20, 2025, 7:00 AM EST - 9 months ago

Skye Bioscience to Present at TD Cowen Health Care Conference

Skye Bioscience Announces Participation in February Conferences

Feb 4, 2025, 7:00 AM EST - 10 months ago

Skye Bioscience Announces Participation in February Conferences

MoneyShow's Best Investment Ideas For 2025: Part 8

Feb 3, 2025, 9:20 AM EST - 10 months ago

MoneyShow's Best Investment Ideas For 2025: Part 8

DELL FNV MNKD MSTR SKE AMSC

Skye Bioscience to Present at J.P. Morgan Healthcare Conference

Dec 19, 2024, 7:00 AM EST - 11 months ago

Skye Bioscience to Present at J.P. Morgan Healthcare Conference

Skye Bioscience: Nimacimab Targets Safer Weight Loss, Speculative Buy

Dec 10, 2024, 8:32 AM EST - 1 year ago

Skye Bioscience: Nimacimab Targets Safer Weight Loss, Speculative Buy

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor

Nov 14, 2024, 7:00 AM EST - 1 year ago

Skye Bioscience Surpasses 50% Patient Enrollment in Phase 2 Obesity Study of Differentiated CB1 Inhibitor

Skye Bioscience, Inc. (SKYE) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 10:36 PM EST - 1 year ago

Skye Bioscience, Inc. (SKYE) Q3 2024 Earnings Call Transcript

Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights

Nov 7, 2024, 4:01 PM EST - 1 year ago

Skye Bioscience Reports Third Quarter 2024 Financial Results and Recent Highlights

Skye Bioscience to Announce Third Quarter 2024 Results

Nov 1, 2024, 7:00 AM EDT - 1 year ago

Skye Bioscience to Announce Third Quarter 2024 Results

HedgeAlerts
HedgeAlerts Nov. 14 at 6:09 PM
Hedge Alert Live - Protect Your Portfolio Contract: $SKYE $2.50 Put · NOV 21, 2025 Exp Entry Price: $1.15 - $1.20 Exit Price Target: $1.95 Profit Margin: +70% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 14 at 5:08 PM
💎 LiquidTheta® Live Actionable Trade Asset: $SKYE Contracts: $SKYE June 18, 2026 $2 Calls Scale in: $0.52- $0.64 Scale out: $2.03-$3.48 Profit Potential : 68% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
YazzJr
YazzJr Nov. 14 at 3:09 PM
$SKYE Not much holding this stock up. We have til what,Feb until we get the results for the 300mg dosage? That is a ways away. If this goes much lower we are going to have to start worrying about NASDAQ compliance issues. Hopefully they can find a partner or a buyer some time soon. Really need some kind of good news here soon.
1 · Reply
HedgeAlerts
HedgeAlerts Nov. 14 at 7:29 AM
Hedge Alert Live - Protect Your Portfolio Contract: $SKYE $2.50 Put · NOV 21, 2025 Exp Entry Price: $1.15 - $1.20 Exit Price Target: $1.77 Profit Margin: +54% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 13 at 10:15 AM
💎 LiquidTheta® Live Actionable Trade Asset: $SKYE Contracts: $SKYE June 18, 2026 $2 Calls Scale in: $0.50- $0.61 Scale out: $1.93-$3.30 Profit Potential : 323% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
iMoveTheMarket
iMoveTheMarket Nov. 13 at 6:06 AM
$SKYE $VKTX I take this back. It’s aweful
0 · Reply
iMoveTheMarket
iMoveTheMarket Nov. 13 at 6:05 AM
$SKYE this is like a dog shit shit a dog shit
1 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 12 at 12:36 PM
💎 LiquidTheta® Live Actionable Trade Asset: $SKYE Contracts: $SKYE June 18, 2026 $2 Calls Scale in: $0.38- $0.47 Scale out: $1.49-$2.55 Profit Potential : 444% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
MissionaryTrader
MissionaryTrader Nov. 12 at 1:38 AM
$SKYE Percentage of float shorted has dropped to 10.18%, this is down from around 19%
2 · Reply
iMoveTheMarket
iMoveTheMarket Nov. 11 at 11:05 PM
$VKTX $SKYE is the underrated stock here. 150mil market cap and its drug doesn’t take weight off but what it does do is it greatly reduces the amount of weight added back on over time
1 · Reply
iMoveTheMarket
iMoveTheMarket Nov. 11 at 9:13 PM
$PFE why is no one trying to buy $SKYE
2 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 11 at 4:12 PM
💎 LiquidTheta® Live Actionable Trade Asset: $SKYE Contracts: $SKYE June 18, 2026 $2 Calls Scale in: $0.43- $0.52 Scale out: $1.66-$2.85 Profit Potential : 159% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
YazzJr
YazzJr Nov. 11 at 1:24 PM
$SKYE That was a brutal Q&A after the conference call. Evercore went right for the jugular and of course, Punit avoided giving the answer. It will be interesting to see what Evercore's new PT is after that.
3 · Reply
YazzJr
YazzJr Nov. 11 at 1:01 PM
$SKYE Well it looks like Pfizer outbid Novo for Metsara. Let's see what Novo does next. https://seekingalpha.com/article/4841334-pfizer-gets-metsera-why-20-65-cvr-is-highly-likely-to-pay-out-in-part
0 · Reply
iMoveTheMarket
iMoveTheMarket Nov. 11 at 1:45 AM
$SKYE this was perhaps the most anti-climactic earnings in history. Company isn’t even capable of a pump n dump
0 · Reply
Maxandbear
Maxandbear Nov. 10 at 9:53 PM
$SKYE
0 · Reply
YazzJr
YazzJr Nov. 10 at 4:46 PM
$SKYE The only real think to pay attention to in today's ER is the cash position. Listen for comments on how they are going to fund the additional testing that is going to have to be done with the higher dosages and the combo'd therapies. Everything else in the ER is basically meaningless.
0 · Reply
Epafroditus
Epafroditus Nov. 10 at 11:09 AM
$SKYE Looking forward. Skye Bioscience to Announce Third Quarter 2025 Financial Results and Business Update on November 10, 2025 Skye will host a conference call on Monday, November 10, 2025 at 1:30 p.m. PT/4:30 p.m. ET to discuss its third quarter 2025 financial results. The Company will issue its financial results and business update press release after the market closes on the same day.
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 8 at 6:34 PM
💎 LiquidTheta® Live Actionable Trade Asset: $SKYE Contracts: $SKYE June 18, 2026 $2 Calls Scale in: $0.47- $0.58 Scale out: $1.84-$3.15 Profit Potential : 216% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
MissionaryTrader
MissionaryTrader Nov. 8 at 12:22 PM
$SKYE
1 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 7 at 4:40 PM
💎 LiquidTheta® Live Actionable Trade Asset: $SKYE Contracts: $SKYE June 18, 2026 $2 Calls Scale in: $0.47- $0.58 Scale out: $1.84-$3.15 Profit Potential : 391% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 6 at 12:46 PM
💎 LiquidTheta® Options Alert Asset: $SKYE Contracts: $SKYE June 18, 2026 $2 Calls Scale in: $0.50- $0.61 Scale out: $1.93-$3.30 Profit Potential : 378% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply